Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NBIX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Parti… NCT05226780 · SCN8A Developmental and Epileptic Encephalopathy Syndrome NBI-921352 | NBIX Neurocrine Biosciences | Phase 2 | Terminated | 8 | Nov 12, 2025 | Registry ↗ |
| Nov 12, 2026 | Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET) NCT07934303 · Friedreich's Ataxia NBIB-0000223 | NBIX Neurocrine Biosciences | Phase 1 | Not yet recruiting | 24 | Nov 2028 | Registry ↗ |
| Nov 12, 2026 | Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia NCT07365462 · Tardive Dyskinesia NBI-1065890, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Recruiting | 100 | Feb 2027 | Registry ↗ |
| Nov 3, 2026 | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Ass… NCT04400331 · Chorea, Huntington Valbenazine | NBIX Neurocrine Biosciences | Phase 3 | Terminated was completed | 154 | Nov 5, 2025 | Registry ↗ |
| Nov 2, 2026 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in… NCT06966401 · Major Depressive Disorder NBI-1065845 | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 850 | May 2029 | Registry ↗ |
| Oct 22, 2026 | A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participant… NCT07196501 · Major Depressive Disorder Osavampator, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 550 | Jul 2028 | Registry ↗ |
| Sep 30, 2026 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Class… NCT07850739 · Congenital Adrenal Hyperplasia NBIP-01435 | NBIX Neurocrine Biosciences | Phase 2 | Not yet recruiting | 36 | Mar 16, 2028 | Registry ↗ |
| Sep 29, 2026 | An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Dis… NCT07288320 · Bipolar I Disorder, Mania NBI-1117568, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Recruiting | 150 | Feb 2028 | Registry ↗ |
| Sep 25, 2026 | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia NCT07227818 · Schizophrenia NBI-1117568, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 560 | Jul 2029 | Registry ↗ |
| Sep 25, 2026 | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia NCT07114874 · Schizophrenia NBI-1117568 | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 600 | Dec 2031 | Registry ↗ |
| Sep 25, 2026 | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia NCT07105098 · Schizophrenia NBI-1117568, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 284 | Nov 2027 | Registry ↗ |
| Sep 22, 2026 | Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a B… NCT07832383 · Alzheimer's Disease NBI-1117567, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Not yet recruiting | 135 | May 2028 | Registry ↗ |
| Sep 18, 2026 | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia… NCT07105111 · Schizophrenia, Schizoaffective Disorder Valbenazine | NBIX Neurocrine Biosciences | Phase 4 | Recruiting | 100 | Jun 2028 | Registry ↗ |
| Aug 11, 2026 | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatm… NCT06911112 · Major Depressive Disorder NBI-1065845, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 200 | Jul 2027 | Registry ↗ |
| Aug 10, 2026 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatm… NCT06963021 · Major Depressive Disorder NBI-1065845, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 200 | Jul 2027 | Registry ↗ |
| Jul 22, 2026 | Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia NCT07288333 · Schizophrenia NBI-1117570, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Recruiting | 120 | Aug 2027 | Registry ↗ |
| Jul 17, 2026 | A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder NCT06267846 · Major Depressive Disorder NBI-1070770, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Completed | 73 | Jul 25, 2025 | Registry ↗ |
| Jun 18, 2026 | Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Asso… NCT06312189 · Chorea, Huntington Valbenazine | NBIX Neurocrine Biosciences | Phase 3 | Enrolling by invitation | 7 | Apr 2028 | Registry ↗ |
| May 11, 2026 | Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia NCT04490915 · Congenital Adrenal Hyperplasia Crinecerfont, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Active, not recruiting | 182 | Jul 19, 2023 | Registry ↗ |
| Apr 29, 2026 | Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskines… NCT05206513 · Dyskinesia, Cerebral Palsy Placebo, Valbenazine | NBIX Neurocrine Biosciences | Phase 3 | Completed | 86 | Oct 16, 2025 | Registry ↗ |
| Mar 6, 2026 | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia NCT06963034 · Schizophrenia NBI-1117568, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 284 | Oct 2027 | Registry ↗ |
| Feb 13, 2026 | Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With… NCT05301894 · Epileptic Encephalopathy, Continuous Spike and Wave During… NBI-827104 | NBIX Neurocrine Biosciences | Phase 2 | Terminated | 19 | Jan 27, 2025 | Registry ↗ |
| Feb 10, 2026 | Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatme… NCT05110157 · Schizophrenia Placebo, Valbenazine | NBIX Neurocrine Biosciences | Phase 3 | Completed | 442 | Feb 4, 2025 | Registry ↗ |
| Jan 16, 2026 | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participan… NCT05859698 · Schizophrenia, Schizoaffective Disorder Valbenazine | NBIX Neurocrine Biosciences | Phase 4 | Completed | 59 | Dec 27, 2024 | Registry ↗ |
| Oct 29, 2025 | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants W… NCT06786624 · Major Depressive Disorder NBI-1065845, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Recruiting | 200 | Jul 2027 | Registry ↗ |
| Oct 16, 2025 | Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epilept… NCT04873869 · SCN8A Developmental and Epileptic Encephalopathy Syndrome NBI-921352, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Terminated | 8 | Mar 17, 2023 | Registry ↗ |
| Sep 5, 2025 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epile… NCT04625101 · Epileptic Encephalopathy, Continuous Spike and Wave During… NBI-827104, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Completed | 24 | Aug 8, 2022 | Registry ↗ |
| Jul 11, 2025 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia NCT05545111 · Schizophrenia NBI-1117568, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Completed | 210 | Jul 10, 2024 | Registry ↗ |
| Jul 2, 2025 | Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cogni… NCT05182476 · Schizophrenia Placebo, Luvadaxistat | NBIX Neurocrine Biosciences | Phase 2 | Terminated | 216 | Jun 28, 2024 | Registry ↗ |
| Feb 5, 2025 | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classi… NCT04806451 · Congenital Adrenal Hyperplasia Crinecerfont, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Active, not recruiting | 103 | Mar 10, 2023 | Registry ↗ |
| Jan 15, 2025 | Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MD… NCT05203341 · Major Depressive Disorder Placebo, NBI-1065845 | NBIX Neurocrine Biosciences | Phase 2 | Completed | 183 | Jan 10, 2024 | Registry ↗ |
| Dec 10, 2024 | VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) NCT03562494 · Parkinson's Disease VY-AADC02, Sham (Placebo) Surgery | NBIX Neurocrine Biosciences | Phase 1 | Completed | 14 | Oct 30, 2024 | Registry ↗ |
| Nov 12, 2024 | Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment… NCT05654870 · Schizophrenia Valbenazine, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Terminated | 8 | Nov 8, 2023 | Registry ↗ |
| Sep 26, 2024 | A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti… NCT05159908 · Focal Onset Seizure, Focal Onset Epilepsy NBI-921352, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Completed | 101 | Aug 21, 2023 | Registry ↗ |
| Jul 31, 2024 | Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhed… NCT05165394 · Anhedonia, Major Depressive Disorder Placebo, NBI-1065846 | NBIX Neurocrine Biosciences | Phase 2 | Completed | 93 | Jul 7, 2023 | Registry ↗ |
| Jul 18, 2024 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatr… NCT04045145 · CAH - Congenital Adrenal Hyperplasia Crinecerfont | NBIX Neurocrine Biosciences | Phase 2 | Completed | 8 | Jul 2, 2021 | Registry ↗ |
| Apr 12, 2024 | Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure M… NCT05493293 · Focal Onset Seizure, Focal Onset Epilepsy NBI-921352 | NBIX Neurocrine Biosciences | Phase 2 | Terminated | 82 | Mar 11, 2024 | Registry ↗ |
| Feb 28, 2024 | A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia NCT03382639 · Schizophrenia Luvadaxistat, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Completed | 256 | Dec 29, 2020 | Registry ↗ |
| Feb 28, 2024 | A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia NCT03359785 · Schizophrenia Luvadaxistat, Matching Placebo | NBIX Neurocrine Biosciences | Phase 2 | Completed | 31 | Dec 21, 2020 | Registry ↗ |
| Dec 22, 2023 | Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies NCT03733496 · Parkinson's Disease | NBIX Neurocrine Biosciences | — | Completed | 14 | Jul 18, 2023 | Registry ↗ |
| Oct 11, 2023 | Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Hunti… NCT04102579 · Chorea, Huntington Valbenazine, Placebo | NBIX Neurocrine Biosciences | Phase 3 | Completed | 128 | Oct 15, 2021 | Registry ↗ |
| Nov 28, 2022 | Opicapone Treatment Initiation Open-Label Study NCT04787965 · Parkinson Disease Opicapone | NBIX Neurocrine Biosciences | — | Completed | 239 | Aug 4, 2022 | Registry ↗ |
| Jul 12, 2022 | Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor NCT04880616 · Essential Tremor NBI-827104, Placebo | NBIX Neurocrine Biosciences | Phase 2 | Completed | 31 | May 25, 2022 | Registry ↗ |
| May 17, 2022 | Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome NCT03530293 · Tourette Syndrome Valbenazine, Placebo oral capsule | NBIX Neurocrine Biosciences | Phase 2 | Terminated | 81 | Jul 16, 2019 | Registry ↗ |
| May 3, 2022 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital… NCT03525886 · CAH - Congenital Adrenal Hyperplasia NBI-74788 | NBIX Neurocrine Biosciences | Phase 2 | Completed | 18 | Apr 7, 2020 | Registry ↗ |
| Apr 19, 2022 | Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome NCT03732534 · Tourette Syndrome NBI-98854 | NBIX Neurocrine Biosciences | Phase 2 | Terminated | 6 | Feb 18, 2019 | Registry ↗ |
| Mar 21, 2022 | Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease NCT03065192 · Idiopathic Parkinson's Disease, Parkinson's Disease VY-AADC01 | NBIX Neurocrine Biosciences | Phase 1 | Completed | 16 | Aug 10, 2021 | Registry ↗ |
| Feb 23, 2022 | Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With… NCT03444038 · Tourette Syndrome Valbenazine | NBIX Neurocrine Biosciences | Phase 2 | Completed | 85 | Jul 12, 2019 | Registry ↗ |
| Jun 30, 2021 | A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharm… NCT04234672 · Healthy Volunteers TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion | NBIX Neurocrine Biosciences | Phase 1 | Completed | 6 | Apr 4, 2020 | Registry ↗ |
| Jun 28, 2021 | Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Touret… NCT03325010 · Tourette Syndrome Valbenazine, Placebo oral capsule | NBIX Neurocrine Biosciences | Phase 2 | Completed | 127 | Nov 1, 2018 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances